ROCKVILLE, Md., May 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company overview at the Rodman and Renshaw 5th Annual Global Healthcare Conference, to be held at the Le Meridien Beach Plaza Hotel in Monte Carlo, May 19-20, 2008. Mr. Burns' presentation is scheduled for Monday, May 19, 2008 at 10:25 a.m. (local time).
As previously mentioned, Mr. Burns' live presentation will be web cast and will serve as the Company's first quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.
EntreMed, Inc. is a clinical-stage pharmaceutical company developing
therapeutic candidates primarily for the treatment of cancer and
inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for
cancer. MKC-1 is an oral cell-cycle regulator with activity against the
mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a
selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The
Company also has an approved IND application for Panzem(R) in rheumatoid
arthritis. EntreMed's goal is to develop and commercialize new compounds
based on the Company's expertise in angiogenesis, cell-cycle regulation and
inflammation - processes vital to the treatment of cancer and other
diseases, such as rheumatoid arthritis. Additional information about
EntreMed is available on the Company's web site at http://www.entremed.com
and in various filings with the Securities and Exchange Commission.
Corporate Communications &Investor Relations
|SOURCE EntreMed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved